Literature DB >> 9342439

The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice.

L Frittitta1, A Cerrato, M G Sacco, N Weidner, I D Goldfine, R Vigneri.   

Abstract

The Insulin Receptor (IR) is a potential oncogene for mammary epithelial cells since its content is increased in most human breast cancer specimens, and both ligand-dependent malignant transformation and ligand-dependent enhanced growth occurs in cultured breast cells overexpressing the IR. To better understand whether the IR plays a role in mammary carcinogenesis which is independent of other initiation factors, we measured IR content in transgenic mouse models of breast cancer induced by 3 known oncogenes (Wnt-1, Neu, and Ret). Insulin receptor content was measured by a specific radioimmunoassay. In normal mammary gland tissues IR content was 14.6 +/- 1.4 ng/mg of protein (mean +/- SEM, n = 6). In the 3 cancers IR content was elevated (Neu = 36.1 +/- 4.6, n = 8, p < 0.002; Wnt-1 = 38.3 +/- 2.6, n = 13, p < 0.001; and Ret = 53.6 +/- 7.1, n = 7, p < 0.001). These data indicate that IR overexpression, in addition to being a potential oncogene, is increased in mouse tumors initiated by other oncogenes, and therefore may also play a supportive role in the growth of breast cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342439     DOI: 10.1023/a:1005801713713

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

Authors:  Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 3.  Insulin, insulin receptors, and cancer.

Authors:  R Vigneri; I D Goldfine; L Frittitta
Journal:  J Endocrinol Invest       Date:  2016-07-01       Impact factor: 4.256

4.  Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

Authors:  Ruslan Novosyadlyy; Danielle E Lann; Archana Vijayakumar; Anne Rowzee; Deborah A Lazzarino; Yvonne Fierz; Joan M Carboni; Marco M Gottardis; Patricia A Pennisi; Alfredo A Molinolo; Naamit Kurshan; Wilson Mejia; Stefania Santopietro; Shoshana Yakar; Teresa L Wood; Derek LeRoith
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

5.  IGF and insulin receptor signaling in breast cancer.

Authors:  Antonino Belfiore; Francesco Frasca
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-19       Impact factor: 2.673

6.  Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.

Authors:  Rosalyn D Ferguson; Ruslan Novosyadlyy; Yvonne Fierz; Nyosha Alikhani; Hui Sun; Shoshana Yakar; Derek Leroith
Journal:  Breast Cancer Res       Date:  2012-01-07       Impact factor: 6.466

7.  Investigation of extracellular medium osmolality depending on zinc application and incubation time on A549 cancer cells.

Authors:  Duygu Tarhan; Nural Pastaci Özsobaci; Dilek Düzgün Ergün; Alev Meltem Ercan
Journal:  J Biol Phys       Date:  2022-03-24       Impact factor: 1.560

8.  Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation.

Authors:  Veronica Vella; Maria Luisa Nicolosi; Marika Giuliano; Andrea Morrione; Roberta Malaguarnera; Antonino Belfiore
Journal:  Cells       Date:  2019-09-01       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.